Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments-Reference-Cited by-同舟云学术

Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments

Published:2023-12-18 Issue:24 Volume:15 Page:5885
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Pons-Riverola Alexandra¹²³,Morillas Herminio¹²³,Berdejo Javier¹²³,Pernas Sonia¹⁴^ORCID,Pomares Helena¹⁵,Asiain Leyre¹⁶,Garay Alberto¹²³,Fernandez-Ortega Adela¹⁴,Oliveira Ana Carla¹⁵⁷,Martínez Evelyn¹⁶⁸,Jiménez-Marrero Santiago¹²³⁹,Pina Elena¹¹⁰,Fort Eduard¹¹^ORCID,Ramos Raúl¹²³,Alcoberro Lídia²³,Hidalgo Encarnación²,Antonio-Rebollo Maite¹²,Alcober Laia¹³,Enjuanes Grau Cristina²³⁹,Comín-Colet Josep²³⁹,Moliner Pedro¹²³⁹^ORCID

Affiliation:

1. Cardio-Oncology Unit, Bellvitge University Hospital—Catalan Institute of Oncology, L’Hospitalet de Llobregat, 08908 Barcelona, Spain

2. Cardiology Department, Bellvitge University Hospital, L’Hospitalet de Llobregat, 08907 Barcelona, Spain

3. Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, 08908 Barcelona, Spain

4. Medical Oncology Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, 08908 Barcelona, Spain

5. Clinical Haematology Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, 08908 Barcelona, Spain

6. Radiation Oncology Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, 08908 Barcelona, Spain

7. Haematopoietic and Lymphoid Tumours Group, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, 08908 Barcelona, Spain

8. Radiobiology and Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, 08908 Barcelona, Spain

9. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain

10. Thrombosis and Haemostasis Unit, Bellvitge University Hospital, L’Hospitalet de Llobregat, 08907 Barcelona, Spain

11. Pharmacy Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, 08908 Barcelona, Spain

12. Oncogeriatrics Department, Catalan Institute of Oncology, L’Hospitalet de Llobregat, 08908 Barcelona, Spain

13. Primary Care Service Delta del Llobregat and IDIAP, Catalan Health Service, 08007 Barcelona, Spain

Abstract

Cardiovascular disease is a common problem in cancer patients that is becoming more widely recognized. This may be a consequence of prior cardiovascular risk factors but could also be secondary to the anticancer treatments. With the goal of offering a multidisciplinary approach to guaranteeing optimal cancer therapy and the early detection of related cardiac diseases, and in light of the recent ESC Cardio-Oncology Guideline recommendations, we developed a Cardio-Oncology unit devoted to the prevention and management of these specific complications. This document brings together important aspects to consider for the development and organization of a Cardio-Oncology program through our own experience and the current evidence.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/24/5885/pdf

Reference46 articles.

1. Shared Risk Factors in Cardiovascular Disease and Cancer;Koene;Circulation,2016

2. Cancer diagnosis in patients with heart failure: Epidemiology, clinical implications and gaps in knowledge;Ameri;Eur. J. Heart Fail.,2018

3. Incidence of cancer in patients with chronic heart failure: A long-term follow-up study;Banke;Eur. J. Heart Fail.,2016

4. Trends in modes of death in heart failure over the last two decades: Less sudden death but cancer deaths on the rise;Moliner;Eur. J. Heart Fail.,2019

5. Fundamentos de las unidades de cardio-oncología;Nhola;Rev. Española Cardiol.,2017